Waldenström's macroglobulinemia historical perspective
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia historical perspective On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia historical perspective |
|
FDA on Waldenström's macroglobulinemia historical perspective |
|
CDC on Waldenström's macroglobulinemia historical perspective |
|
Waldenström's macroglobulinemia historical perspective in the news |
|
Blogs on Waldenström's macroglobulinemia historical perspective |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2], Roukoz A. Karam, M.D.[3]; Grammar Reviewer: Natalie Harpenau, B.S.[4]
Overview
Waldenström macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 1944. Bing-Neel syndrome, a late and rare complication of Waldenstrom's macroglobulinemia, was first discovered in 1936 by Jens Bing and Axel Valdemar Neel. First report on familial aggregation of Waldenstrom macroglobulinemia was published in 1962. In 1944, Revised European-American classification of lymphoid neoplasms (REAL) and WHO in 2001, placed Waldenstrom macroglobulinemia in the category of lymphoplasmacytic lymphoma. A diagnostic criteria for Waldenstrom macroglobulinemia was proposed by a consensus group at the Second International Workshop in Athens, Greece in 2002. A report published in 2013 showed that a patient of Bing-Neel syndrome who discontinued the treatment in 2009 remained asymptomatic.
Historical Perspective
- In 1936, Jens Bing and Axel Valdemar Neel, discovered a late and rare complication of Waldenstrom's macroglobulinemia known as Bing-Neel syndrome (BNS), who observed a case of 2 women, 56 and 39 years old, presenting with rapid neurodegeneration in the setting of hyperglobulinemia
- In 1944, Jan G. (Gosta) Waldenstrom, a Swedish doctor of internal medicine, first discovered Waldenstrom macroglobulinemia (WM) who reported an unusual presentation of fatigue, lymphadenopathy, bleeding from nose and mouth, worsening anemia, elevated sedimentation rate, low serum fibrinogen levels (hypofibrinogenemia), hyperviscosity, and hypergammaglobulinemia in two patients due to increased levels of a class of an abnormal high molecular weight serum protein called macroglobulins[1][2]
- In 1962, the first report on familial inheritance in WM was published, and since then many cohort studies as well as small case-control studies have been published showing familial aggregation of WM[3][4][5][6][7][8][9][10][11] [12][13][14][15]
- In 1994, a Revised European-American classification of lymphoid neoplasms (REAL) was published by International Lymphoma Study Group which placed WM in the category of lymphoplasmacytic lymphoma (an indolent subtype of Non Hodgkin's lymphoma and it is based on the morphology, immunophenotype, genetic and clinical features[16][17]
- In 2001, WHO also classified the pathology of WM as lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia based on REAL classification[2]
- In September 26-30, 2002, a consensus group at the Second International Workshop on WM in Athens, Greece, defined WM as a distinct clinicopathologic entity with characteristics of bone marrow infiltration associated with IgM monoclonal gammopathy by WM and proposed a diagnostic criteria for WM[2][18]
- In 2009, in Arkansas, a patient of Bing-Neel syndrome discontinued the treatment for BNS which included, intrathecal chemotherapy with several cycles of systemic chemotherapy followed by autologous BEAM transplant. In 2013, the patient was still asymptomatic when a follow-up report was published[19]
References
- ↑ Waldenström, Jan (2009). "Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia - a new syndrome?". Acta Medica Scandinavica. 117 (3–4): 216–247. doi:10.1111/j.0954-6820.1944.tb03955.x. ISSN 0001-6101.
- ↑ 2.0 2.1 2.2 Konoplev, Sergej; Medeiros, L. Jeffrey; Bueso-Ramos, Carlos E.; Jorgensen, Jeffrey L.; Lin, Pei (2005). "Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia". American Journal of Clinical Pathology. 124 (3): 414–420. doi:10.1309/3G1XDX0DVHBNVKB4. ISSN 0002-9173.
- ↑ MASSARI R, FINE JM, METAIS R (1962). "Waldenstrom's macroglobulinaemia observed in two brothers". Nature. 196: 176–8. PMID 13933388.
- ↑ Altieri A, Bermejo JL, Hemminki K (2005). "Familial aggregation of lymphoplasmacytic lymphoma with non-Hodgkin lymphoma and other neoplasms". Leukemia. 19 (12): 2342–3. doi:10.1038/sj.leu.2403991. PMID 16224483.
- ↑ Blattner WA, Garber JE, Mann DL, McKeen EA, Henson R, McGuire DB; et al. (1980). "Waldenström's macroglobulinemia and autoimmune disease in a family". Ann Intern Med. 93 (6): 830–2. PMID 6778280.
- ↑ Fine JM, Lambin P, Massari M, Leroux P (1982). "Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenström's macroglobulinemia". Acta Med Scand. 211 (3): 237–9. PMID 6805257.
- ↑ Fine JM, Muller JY, Rochu D, Marneux M, Gorin NC, Fine A; et al. (1986). "Waldenström's macroglobulinemia in monozygotic twins". Acta Med Scand. 220 (4): 369–73. PMID 3099545.
- ↑ Gétaz EP, Staples WG (1977). "Familial Waldenström's macroglobulinaemia: a case report". S Afr Med J. 51 (24): 891–2. PMID 408931.
- ↑ Linet MS, Humphrey RL, Mehl ES, Brown LM, Pottern LM, Bias WB; et al. (1993). "A case-control and family study of Waldenstrom's macroglobulinemia". Leukemia. 7 (9): 1363–9. PMID 8371587.
- ↑ Ogmundsdóttir HM, Jóhannesson GM, Sveinsdóttir S, Einarsdóttir S, Hegeman A, Jensson O; et al. (1994). "Familial macroglobulinaemia: hyperactive B-cells but normal natural killer function". Scand J Immunol. 40 (2): 195–200. PMID 8047841.
- ↑ Seligmann M, Danon F, Mihaesco C, Fudenberg HH (1967). "Immunoglobulin abnormalities in families of patients with Waldenström's macroglobulinemia". Am J Med. 43 (1): 66–83. PMID 4143650.
- ↑ Taleb N, Tohme A, Abi Jirgiss D, Kattan J, Salloum E (1991). "Familial macroglobulinemia in a Lebanese family with two sisters presenting Waldenström's disease". Acta Oncol. 30 (6): 703–5. PMID 1958390.
- ↑ Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C; et al. (2006). "Characterization of familial Waldenstrom's macroglobulinemia". Ann Oncol. 17 (3): 488–94. doi:10.1093/annonc/mdj111. PMID 16357024.
- ↑ Youinou P, le Goff P, Saleun JP, Rivat L, Morin JF, Fauchier C; et al. (1978). "Familial occurrence of monoclonal gammapathies". Biomedicine. 28 (4): 226–32. PMID 104746.
- ↑ Renier G, Ifrah N, Chevailler A, Saint-Andre JP, Boasson M, Hurez D (1989). "Four brothers with Waldenstrom's macroglobulinemia". Cancer. 64 (7): 1554–9. PMID 2505923.
- ↑ Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J; et al. (1999). "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997". J Clin Oncol. 17 (12): 3835–49. doi:10.1200/JCO.1999.17.12.3835. PMID 10577857.
- ↑ Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML; et al. (1994). "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood. 84 (5): 1361–92. PMID 8068936.
- ↑ Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
- ↑ Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F; et al. (2013). "Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature". Clin Lymphoma Myeloma Leuk. 13 (4): 502–6. doi:10.1016/j.clml.2013.03.002. PMID 23747080.